retatrutide diabetes type 2 Retatrutide—A Game Changer in Obesity Pharmacotherapy ESC 2024: Retatrutide improves lipid

In this role, M.H.T

Ewald, C

Ongoing studies suggest further therapeutic benefits beyond its approved uses

The Opportunity The pharmacy benefit management (PBM) market valued at $548 billion in 2023 and projected to grow to $898 billion by 2032 is rife with inefficiencies that drive up costs and limit accessibility

If side effects are significant even at this dose, it may indicate the need for a slower escalation plan

Exploring African botanicals and medicinal plants for new nutrition solutions The nutrition industry continued to explore new plants and compounds for their health benefits in 2025, with suppliers of African botanicals highlighting the continents diverse native species many of which are still underrepresented in global markets